Wall Street brokerages forecast that Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) will announce sales of $1.56 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from $1.30 million to $1.88 million. Tetraphase Pharmaceuticals posted sales of $1.24 million in the same quarter last year, which suggests a positive year over year growth rate of 25.8%. The business is expected to report its next earnings results on Thursday, August 3rd.

On average, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $1.56 million for the current financial year, with estimates ranging from $4.99 million to $7.11 million. For the next financial year, analysts expect that the firm will post sales of $5.13 million per share, with estimates ranging from $3.00 million to $7.51 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative return on equity of 60.55% and a negative net margin of 1,932.24%. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.46 million. During the same period last year, the company posted ($0.46) earnings per share. The business’s quarterly revenue was down 24.5% on a year-over-year basis.

Several equities analysts have issued reports on TTPH shares. BMO Capital Markets reissued a “buy” rating and issued a $12.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 5th. HC Wainwright started coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $8.45.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 7.80 on Friday. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93. The company’s 50-day moving average is $7.48 and its 200-day moving average is $6.43. The stock’s market capitalization is $296.06 million.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after buying an additional 230,420 shares in the last quarter. Tekla Capital Management LLC raised its stake in Tetraphase Pharmaceuticals by 422.2% in the first quarter. Tekla Capital Management LLC now owns 1,004,322 shares of the biopharmaceutical company’s stock valued at $9,230,000 after buying an additional 812,000 shares in the last quarter. State Street Corp raised its stake in Tetraphase Pharmaceuticals by 1.6% in the fourth quarter. State Street Corp now owns 710,982 shares of the biopharmaceutical company’s stock valued at $2,864,000 after buying an additional 11,391 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Tetraphase Pharmaceuticals by 180.4% in the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock valued at $5,829,000 after buying an additional 408,078 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in Tetraphase Pharmaceuticals by 108.2% in the first quarter. Acadian Asset Management LLC now owns 379,049 shares of the biopharmaceutical company’s stock valued at $3,482,000 after buying an additional 197,022 shares in the last quarter. Institutional investors and hedge funds own 47.77% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Analysts Expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Will Announce Quarterly Sales of $1.56 Million” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/07/15/analysts-expect-tetraphase-pharmaceuticals-inc-nasdaqttph-will-announce-quarterly-sales-of-1-56-million.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.